Can a patient with type 2 diabetes diagnosed with dementia have increased rate of mortality?
Read More »Canagliflozin Study Stopped Early Due to Positive Results in Reducing CKD, Death and ESRD
Featuring exclusive comments from Dr. George Bakris
Studies are rarely stopped early; when it happens, we should take notice of the results.
Is Metformin Therapy Safe For Use In Stage 3 Chronic Kidney Disease?
Metformin may help lower the risk of cardiovascular events and death in patients with moderate to severe renal function.
Read More »New FDA Extension for Farxiga and Xigduo XR
Dapagliflozin’s updated package insert confirms efficacy and safety profile for patients with moderate chronic kidney disease.
Read More »Diabetes and Chronic Kidney Disease
Older adults with diabetes and chronic kidney disease (CKD) are at an increased risk of cognitive impairment and dementia, frailty, dysglycemia, and polypharmacy.
Read More »Metformin Safety In Patients With Chronic Kidney Disease And Its Benefits
In patients with stage 3 kidney disease, metformin use may be safe and may reduce the risk of mortality and cardiovascular events.
Read More »Reducing End-Stage Kidney Disease Risk More Efficiently
Use of albuminuria level changes as the endpoint to determine need to reduce albumin-to-creatinine ratio.
Read More »Albuminuria Change and Risk of End-Stage Kidney Disease
Change in albuminuria as surrogate endpoint for progression of chronic kidney disease strongly supported by biological plausibility, but empirical evidence to support its validity in epidemiological studies lacking.
Read More »Albuminuria Change and Risk of End-Stage Kidney Disease
Change in albuminuria as a surrogate endpoint for progression of chronic kidney disease strongly supported by biological plausibility, but empirical evidence to support validity in epidemiological studies still lacking.
Read More »Proteins Predict Progression and Mortality of Kidney Disease
Researchers develop way to measure abundance of 12 different complement proteins in the urine.
Read More »